Mammalian son of sevenless guanine nucleotide exchange factors: Old concepts and new perspectives

Genes and Cancer

Volumn 2, Issue 3, 2011, Pages 298-305

  Rojas, José M ^a   Oliva, José Luis ^a   Santos, Eugenio ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Ras; Ras GEF; RTK; Signaling; Sos

Indexed keywords

MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAF INHIBITOR; SOS PROTEIN; SOS2 PROTEIN; UCS 15A; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; DRUG PROTEIN BINDING; GENE MUTATION; GINGIVA FIBROMATOSIS; HUMAN; METASTASIS INHIBITION; NONHUMAN; NOONAN SYNDROME; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

DROSOPHILA MELANOGASTER; MAMMALIA; MUS;

EID: 79960066478     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911408078     Document Type: Review

References (103)

1. Rojas JM, Santos E. Ras genes and human cancer: different implications and different roles. Curr Genomics. 2002;3:295-311.
2. Wittinghofer A, Nassar N. How Ras-related proteins talk to their effectors. Trends Biochem Sci. 1996;21:488-91.
3. Wittinghofer A, Scheffzek K, Ahmadian MR. The interaction of Ras with GTPase-activating proteins. FEBS Lett. 1997;410:63-7.
4. Downward J. Control of ras activation. Cancer Surv. 1996;27:87-100.
5. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta. 2008;1786:178-87.
6. Boguski M, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643-54.
7. Guerrero C, Rojas JM, Chedid M, et al. Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines. Oncogene. 1996;12:1097-107.
8. Schlessinger J. How receptor tyrosine kinases activate Ras. Trends Biochem Sci. 1993;18:273-6.
9. Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature. 1995;376:524-7.
10. Martegani E, Vanoni M, Zippel R, et al. Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator. EMBO J. 1992;11:2151-7.
11. Brambilla R, Gnesutta N, Minichiello L, et al. A role for the Ras signalling pathway in synaptic transmission and long-term memory. Nature. 1997;390:281-6.
12. Wei W, Schreiber SS, Baudry M, Tocco G, Broek D. Localization of the cellular expression pattern of cdc25NEF and ras in the juvenile rat brain. Brain Res Mol Brain Res. 1993;19:339-44.
13. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC. RasGRP, a Ras guanyl nucleotidereleasing protein with calcium- and diacylglycerol- binding motifs. Science. 1998;280:1082-6.
14. Tognon CE, Kirk HE, Passmore LA, Whitehead IP, Der CJ, Kay RJ. Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol Cell Biol. 1998;18:6995-7008.
15. Reuther GW, Lambert QT, Rebhun JF, Caligiuri MA, Quilliam LA, Der CJ. RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. J Biol Chem. 2002;277:30508-14.
16. Simon MA, Bowtell DD, Dodson GS, Laverty TR, Rubin GM. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell. 1991;67:701-16.
17. Chang C, Hopper NA, Sternberg PW. Caenorhabditis elegans SOS-1 is necessary for multiple RAS-mediated developmental signals. EMBO J. 2000;19:3283-94.
18. Bowtell D, Fu P, Simon M, Senior P. Identification of murine homologues of the Drosophila son of sevenless gene: potential activators of ras. Proc Natl Acad Sci U S A. 1992;89:6511-5.
19. Chardin P, Camonis JH, Gale NW, et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 1993;260:1338-43.
20. Chardin P, Mattei MG. Chromosomal localization of two genes encoding human ras exchange factors: SOS1 maps to the 2p22-->p16 region and SOS2 to the 14q21-->q22 region of the human genome. Cytogenet Cell Genet. 1994;66:68-9.
21. Rojas JM, Coque JJR, Guerrero C, et al. A 15 amino acid stretch close to the Grb2-binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity. Oncogene. 1996;12:2291-300.
22. Rojas JM, Subleski M, Coque JJ, et al. Isoform- specific insertion near the Grb2-binding domain modulates the intrinsic guanine nucleotide exchange activity of hSos1. Oncogene. 1999;18:1651-61.
23. Nielsen KH, Papageorge AG, Vass WC, Willumsen BM, Lowy DR. The Ras-specific exchange factors mouse Sos1 (mSos1) and mSos2 are regulated differently: mSos2 contains ubiquitination signals absent in mSos1. Mol Cell Biol. 1997;17:7132-8.
24. Qian X, Esteban L, Vass WC, et al. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties. EMBO J. 2000;19:642-54.
25. Rogge RD, Karlovich CA, Banerjee U. Genetic dissection of a neurodevelopmental pathway: Son of Sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases. Cell. 1991;64:39-48.
26. Esteban LM, Fernandez-Medarde A, Lopez E, et al. Ras-guanine nucleotide exchange factor sos2 is dispensable for mouse growth and development. Mol Cell Biol. 2000;20:6410-3.
27. Wang DZ, Hammond VE, Abud HE, Bertoncello I, McAvoy JW, Bowtell DD. Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development. Genes Dev. 1997;11:309-20.
28. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J. The structural basis of the activation of Ras by Sos. Nature. 1998;394:337-43.
29. Sondermann H, Soisson SM, Boykevisch S, Yang SS, Bar-Sagi D, Kuriyan J. Structural analysis of autoinhibition in the Ras activator Son of Sevenless. Cell. 2004;119:393-405.
30. Wang W, Fisher E, Jia Q, et al. The Grb2 binding domain of mSos1 is not required for downstream signal transduction. Nature Gen. 1995;10:294-300.
31. Karlovich CA, Bonfini L, McCollam L, et al. In vivo functional analysis of the Ras exchange factor son of sevenless. Science. 1995;268:576-9.
32. Byrne JL, Paterson HF, Marshall CJ. P21Ras activation by the guanine nucleotide exchange factor Sos, requires the Sos/Grb2 interaction and a second ligand-dependent signal involving the Sos N-terminus. Oncogene. 1996;13:2055-65.
33. Zheng J, Chen RH, Corblan-Garcia S, Cahill SM, Bar-Sagi D, Cowburn D. The solution structure of the pleckstrin homology domain of human SOS1: a possible structural role for the sequential association of diffuse B cell lymphoma and pleckstrin homology domains. J Biol Chem. 1997;272:30340-4.
34. Koshiba S, Kigawa T, Kim JH, Shirouzu M, Bowtell D, Yokoyama S. The solution structure of the pleckstrin homology domain of mouse Son-of-sevenless 1 (mSos1). J Mol Biol. 1997;269:579-91.
35. Rameh LE, Arvidsson A, Carraway KL 3rd, et al. A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. J Biol Chem. 1997;272:22059-66.
36. Qian X, Vass WC, Papageorge AG, Anborgh PH, Lowy DR. N terminus of Sos1 Ras exchange factor: critical roles for the Dbl and pleckstrin homology domains. Mol Cell Biol. 1998;18:771-8.
37. Corbalan-Garcia S, Margarit SM, Galron D, Yang SS, Bar-Sagi D. Regulation of Sos activity by intramolecular interactions. Mol Cell Biol. 1998;18:880-6.
38. Hall BE, Yang SS, Bar-Sagi D. Autoinhibition of Sos by intramolecular interactions. Front Biosci. 2002;7:288-94.
39. Margarit SM, Sondermann H, Hall BE, et al. Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell. 2003;112:685-95.
40. Jorge R, Zarich N, Oliva JL, et al. HSos1 contains a new amino-terminal regulatory motif with specific binding affinity for its pleckstrin homology domain. J Biol Chem. 2002;277:44171-9.
41. Sondermann H, Soisson SM, Bar-Sagi D, Kuriyan J. Tandem histone folds in the structure of the N-terminal segment of the ras activator Son of Sevenless. Structure (Camb). 2003;11:1583-93.
42. Gureasko J, Kuchment O, Makino DL, Sondermann H, Bar-Sagi D, Kuriyan J. Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A. 2010;107:3430-5.
43. Li N, Batzer A, Daly R, et al. Guanine-nucleotide- releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature. 1993;363:85-8.
44. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature. 1993;363:83-5.
45. Lim WA, Richards FM. Critical residues in an SH3 domain from Sem-5 suggest a mechanism for proline-rich peptide recognition. Nat Struct Biol. 1994;1:221-5.
46. Feng S, Chen JK, Yu H, Simon JA, Schreiber SL. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science. 1994;266:1241-7.
47. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell. 1994;76:933-45.
48. Chardin P, Cussac D, Maignan S, Ducruix A. The Grb2 adaptor. FEBS Lett. 1995;369:47-51.
49. Cussac D, Vidal M, Leprince C, et al. A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J. 1999;13:31-8.
50. Simon JA, Schreiber SL. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions. Chem Biol. 1995;2:53-60.
51. Sudol M. From Src homology domains to other signaling modules: proposal of the protein recognition code. Oncogene. 1998;17:1469-74.
52. Zarich N, Oliva JL, Jorge R, Santos E, Rojas JM. The isoform-specific stretch of hSos1 defines a new Grb2-binding domain. Oncogene. 2000;19:5872-83.
53. Kim JH, Shirouzu M, Kataoka T, Bowtell D, Yokoyama S. Activation of Ras and its downstream extracellular signal-regulated protein kinases by the CDC25 homology domain of mouse Son-of-sevenless 1 (mSos1). Oncogene. 1998;16:2597-607.
54. Hart TC, Zhang Y, Gorry MC, et al. A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. Am J Hum Genet. 2002;70:943-54.
55. Douville E, Downward J. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene. 1997;15:373-83.
56. Zarich N, Oliva JL, Martinez N, et al. Grb2 is a negative modulator of the intrinsic Ras-GEF activity of hSos1. Mol Biol Cell. 2006;17:3591-7.
57. Pawson T, Schlessinger J. SH2 and SH3 domains. Curr Biol. 1993;3:4345-442.
58. McCormick F. How receptors turn Ras on. Nature. 1993;363:15-6.
59. Egan S, Weinberg R. The pathway to signal achievement. Nature. 1993;365:781-3.
60. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol. 2007;9:706-12.
61. Yadav KK, Bar-Sagi D. Allosteric gating of Son of Sevenless activity by the histone domain. Proc Natl Acad Sci U S A. 2010;107:3436-40.
62. Hall BE, Yang SS, Boriack-Sjodin PA, Kuriyan J, Bar-Sagi D. Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange. J Biol Chem. 2001;276:27629-37.
63. Jaumot M, Yan J, Clyde-Smith J, Sluimer J, Hancock JF. The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 2002;277:272-8.
64. Arozarena I, Matallanas D, Berciano MT, et al. Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors. Mol Cell Biol. 2004;24:1516-30.
65. Nimnual AS, Yatsula BA, Bar-Sagi D. Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science. 1998;279:560-3.
66. Scita G, Nordstrom J, Carbone R, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 1999;401:290-3.
67. Scita G, Tenca P, Areces LB, et al. An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actinpolymerizing machine. J Cell Biol. 2001;27:27.
68. Chen PC, Wakimoto H, Conner D, et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest. 2010;120:4353-65.
69. Innocenti M, Tenca P, Frittoli E, et al. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol. 2002;156:125-36.
70. Cherniack A, Klarlund J, Czech M. Phosphorylation of the Ras nucleotide exchange factor son of sevenless by mitogen-activated protein kinase. J Biol Chem. 1994;269:4717-20.
71. Furuta S, Miura K, Copeland T, Shang WH, Oshima A, Kamata T. Light chain 3 associates with a Sos1 guanine nucleotide exchange factor: its significance in the Sos1-mediated Rac1 signaling leading to membrane ruffling. Oncogene. 2002;21:7060-6.
72. Swanson KD, Winter JM, Reis M, et al. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer. 2008;47:253-9.
73. Timofeeva OA, Zhang X, Ressom HW, et al. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African- American men. Int J Oncol. 2009;35:751-60.
74. Chen H, Wu X, Pan ZK, Huang S. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res. 2010;70:9979-90.
75. Noonan JA. Hypertelorism with Turner phenotype: a new syndrome with associated congenital heart disease. Am J Dis Child. 1968;116:373-80.
76. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2-26.
77. Pandit B, Sarkozy A, Pennacchio LA, et al. Gainof- function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007-12.
78. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007;39:1013-7.
79. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38:331-6.
80. Cordeddu V, di Schiavi E, Pennacchio LA, et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonanlike syndrome with loose anagen hair. Nat Genet. 2009;41:1022-6.
81. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39:70-4.
82. Zenker M, Horn D, Wieczorek D, et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet. 2007;44:651-6.
83. Hasle H. Malignant diseases in Noonan syndrome and related disorders. Horm Res. 2009;72 Suppl 2:8-14.
84. Cotton JL, Williams RG. Noonan syndrome and neuroblastoma. Arch Pediatr Adolesc Med. 1995;149:1280-1.
85. Lopez-Miranda B, Westra SJ, Yazdani S, Boechat MI. Noonan syndrome associated with neuroblastoma: a case report. Pediatr Radiol. 1997;27:324-6.
86. Jongmans MC, Hoogerbrugge PM, Hilkens L, et al. Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma. Genes Chromosomes Cancer. 2010;49:635-41.
87. Moschovi M, Touliatou V, Papadopoulou A, Mayakou MA, Nikolaidou-Karpathiou P, Kitsiou-Tzeli S. Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. J Pediatr Hematol Oncol. 2007;29:341-4.
88. Cohen MM Jr., Gorlin RJ. Noonan-like/ multiple giant cell lesion syndrome. Am J Med Genet. 1991;40:159-66.
89. Neumann TE, Allanson J, Kavamura I, et al. Multiple giant cell lesions in patients with Noonan syndrome and cardio-faciocutaneous syndrome. Eur J Hum Genet. 2009; 17:420-5.
90. Jang SI, Lee EJ, Hart PS, Ramaswami M, Pallos D, Hart TC. Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis. J Biol Chem. 2007;282:20245-55.
91. Sibilia M, Fleischmann A, Behrens A, et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell. 2000;102:211-20.
92. Sharma SV, Oneyama C, Yamashita Y, et al. UCS15A, a non-kinase inhibitor of Src signal transduction. Oncogene. 2001;20:2068-79.
93. Oneyama C, Nakano H, Sharma SV. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene. 2002;21:2037-50.
94. Oneyama C, Agatsuma T, Kanda Y, et al. Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A. Chem Biol. 2003;10:443-51.
95. Hashimoto S, Hirose M, Hashimoto A, et al. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. Proc Natl Acad Sci U S A. 2006;103:7036-41.
96. Oliva JL, Perez-Sala D, Castrillo A, et al. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc Natl Acad Sci U S A. 2003;100:4772-7.
97. Renedo M, Gayarre J, Garcia-Dominguez CA, et al. Modification and activation of Ras proteins by electrophilic prostanoids with different structure are site-selective. Biochemistry. 2007;46:6607-16.
98. Lander HM, Hajjar DP, Hempstead BL, et al. A molecular redox switch on p21(ras): structural basis for the nitric oxide-p21(ras) interaction. J Biol Chem. 1997;272:4323-6.
99. Mott HR, Carpenter JW, Campbell SL. Structural and functional analysis of a mutant Ras protein that is insensitive to nitric oxide activation. Biochemistry. 1997;36:3640-4.
100. Lander HM, Ogiste JS, Pearce SF, Levi R, Novogrodsky A. Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J Biol Chem. 1995;270:7017-20.
101. Steenland K, Bertazzi P, Baccarelli A, Kogevinas M. Dioxin revisited: developments since the 1997 IARC classification of dioxin as a human carcinogen. Environ Health Perspect. 2004;112:1265-8.
102. Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007;581:3608-15.
103. Pierre S, Bats AS, Chevallier A, et al. Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation. Biochem Pharmacol. 2011;81:304-13.